Meine Merkliste
my.bionity.com  
Login  

Introduction

Global Market Direct’s pharmaceuticals report, “ELORAC, Inc. - Product Pipeline Review - Q1 2011” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- ELORAC, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of ELORAC, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of ELORAC, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the ELORAC, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Highlights

Reasons to buy

- Evaluate ELORAC, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of ELORAC, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the ELORAC, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with ELORAC, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of ELORAC, Inc. and identify potential opportunities in those areas.

Pharma / Arzneimittel   Marktstudie
Jahrgang:   2011
Herausgeber:   Global Markets Direct
Preis:   500.00€

Marktstudie bestellen

Bestellen Sie die Marktstudie bei markt-studie.de

Merkliste

Hier setzen Sie die nebenstehende Marktstudie auf Ihre persönliche Merkliste.

Mehr über Global Markets Direct
Ihr Bowser ist nicht aktuell. Microsoft Internet Explorer 6.0 unterstützt einige Funktionen auf Chemie.DE nicht.